Cash-pretty Australian Biotech Biota Returns $20 Million To Shareholders
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Just days after unveiling positive results from Phase III trials on its second-generation flu treatment laninamivir, co-developed with Daiichi Sankyo, Aussie Biotech Biota announced Aug. 13 that it would issue AU$20 million to its shareholders
You may also be interested in...
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo
As GSK Triples Capacity On Flu Drug Relenza, Royalties Trickle In For Aussie Originator Biota
PERTH, Australia - GlaxoSmithKline's announcement that it will triple its manufacturing capacity of antiviral Relenza is good news for Australian biotech Biota, the developer of the first-in-class neuraminidase inhibitor for which Biota receives 7 percent royalties on global sales
Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31